Petros Pharmaceuticals, Inc. Operating Lease Cost
Petros Pharmaceuticals, Inc. (PTPI) reported Operating Lease Cost of $142.75 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2023-12-31 was $44.81K, a 0.00% change year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2023-09-30 was $44.81K, a 0.00% change year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2023-06-30 was $44.81K, a 0.00% change year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2023-03-31 was $44.81K, a 0.00% change year-over-year.
- Petros Pharmaceuticals, Inc. operating lease, cost for fiscal 2024 was $142.75K, a 20.36% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. operating lease, cost for fiscal 2023 was $179.25K, a 0.00% change from fiscal 2022.
- Petros Pharmaceuticals, Inc. operating lease, cost for fiscal 2022 was $179.25K, a 0.00% change from fiscal 2021.
- Petros Pharmaceuticals, Inc. operating lease, cost for fiscal 2021 was $179.25K, a 0.00% change from fiscal 2020.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $142.75K 10-K · filed 2025-03-31 | |||
| 2023-12-31 | $44.81K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $89.62K derived: sum of 2 quarters · filed 2025-03-31 | $134.43K derived: sum of 3 quarters · filed 2025-03-31 | $179.25K 10-K · filed 2025-03-31 |
| 2023-09-30 | $44.81K 10-Q · filed 2023-11-15 | $89.62K derived: sum of 2 quarters · filed 2023-11-15 | $134.44K 10-Q · filed 2023-11-15 | $179.25K derived: sum of 4 quarters · filed 2024-04-01 |
| 2023-06-30 | $44.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $89.62K 10-Q · filed 2023-08-14 | $134.43K derived: sum of 3 quarters · filed 2024-04-01 | $179.25K derived: sum of 4 quarters · filed 2024-04-01 |
| 2023-03-31 | $44.81K 10-Q · filed 2023-08-14 | $89.62K derived: sum of 2 quarters · filed 2024-04-01 | $134.44K derived: sum of 3 quarters · filed 2024-04-01 | $179.25K derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-12-31 | $44.81K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $89.62K derived: sum of 2 quarters · filed 2024-04-01 | $134.43K derived: sum of 3 quarters · filed 2024-04-01 | $179.25K 10-K · filed 2024-04-01 |
| 2022-09-30 | $44.81K 10-Q · filed 2023-11-15 | $89.62K derived: sum of 2 quarters · filed 2023-11-15 | $134.44K 10-Q · filed 2023-11-15 | $179.25K derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | $44.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $89.62K 10-Q · filed 2023-08-14 | $134.43K derived: sum of 3 quarters · filed 2023-08-14 | $179.25K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $44.81K 10-Q · filed 2023-08-14 | $89.62K derived: sum of 2 quarters · filed 2023-08-14 | $134.44K derived: sum of 3 quarters · filed 2023-08-14 | $179.25K derived: sum of 4 quarters · filed 2023-08-14 |
| 2021-12-31 | $44.81K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $89.62K derived: sum of 2 quarters · filed 2023-03-31 | $134.44K derived: sum of 3 quarters · filed 2023-03-31 | $179.25K 10-K · filed 2023-03-31 |
| 2021-09-30 | $44.81K 10-Q · filed 2021-11-15 | $89.62K derived: sum of 2 quarters · filed 2021-11-15 | $134.44K 10-Q/A · filed 2022-11-15 | $134.44K derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-06-30 | $44.81K 10-Q · filed 2021-08-16 | $89.62K 10-Q · filed 2022-08-12 | $89.62K derived: sum of 3 quarters · filed 2022-05-16 | $134.44K derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-03-31 | $44.81K 10-Q · filed 2022-05-16 | $44.81K derived: sum of 2 quarters · filed 2022-05-16 | $89.62K derived: sum of 3 quarters · filed 2022-05-16 | $134.44K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $44.81K derived: sum of 2 quarters · filed 2022-03-31 | $89.62K derived: sum of 3 quarters · filed 2022-03-31 | $179.25K 10-K · filed 2022-03-31 |
| 2020-09-30 | $44.81K 10-Q · filed 2021-11-15 | $89.62K derived: sum of 2 quarters · filed 2021-11-15 | $179.25K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $44.81K 10-Q · filed 2021-08-16 | $89.62K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $44.81K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |